Colposeptine 18 vaginal tablets — Made in Netherlands — Free Delivery

Vaginal atrophy due to estrogen deficiency in case of subclinical infection.

1 tablet (previously moistened with water) is injected deep into the vagina for 18 days in the evening before going to bed. it is better to do this while lying on your back, with your knees slightly bent. treatment should be started on any day of the menstrual cycle and not interrupted for the duration of menstruation.

The duration of treatment is usually 18 days.

Children. The preparation should not be used in children.

Hypersensitivity to any component of the preparation.

Despite the absence of systemic effects, the preparation should not be used, like any estrogens, with a history of estrogen-dependent tumors.

Breast-feeding (see Use during pregnancy or lactation).

In combination with spermicides (see INTERACTIONS).

By frequency, adverse reactions are divided into the following categories: very often (≥1 / 10); often (≥1/100 to 1/10); infrequently (≥ 1/1000 to 1/100); rarely (≥1/10,000, 1/1000); very rarely (1/10,000); unknown (cannot be estimated from the available data).

From the immune system: unknown - hypersensitivity.

From the skin and subcutaneous tissue: unknown - itching at the site of application.

From the reproductive system and mammary glands: unknown - vulvovaginal discomfort, vaginal bleeding.

Before starting treatment, you should undergo a complete medical examination and confirm the diagnosis. a classic gynecological examination is mandatory, including a smear for bacterial culture.

During treatment, medical supervision is necessary.

Cases of vaginal bleeding have been reported during the use of the preparation chlorquinaldol/promestrin, vaginal tablet. In case of bleeding, it is necessary to stop treatment and determine its etiology.

Chlorquinaldol is a halogenated hydroxyquinoline. Cases of cross-allergy with clioquinol, another halogenated hydroxyquinoline, have been reported.

Use during pregnancy or lactation. Pregnancy. Colposeptin is not indicated for use during pregnancy.

In clinical practice, the results of numerous epidemiological studies make it possible to exclude the risk of malformations due to the use of estrogens alone or in combination at the beginning of pregnancy, in contrast to diethylstilbestrol. As a result, in the event of pregnancy, when using estrogens, there is no need to interrupt it.

Lactation. Systemic resorption of promestine is weak. Colposeptine should be avoided during lactation due to the lack of data on its passage into breast milk.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Does not affect.